   1     . 2.


                         .                              . T                                 . 2.1





      T      the association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorhisms and Parkinson’s disease 21. T              1 T1    T1 TT1         .


T            T1  TT1   . T                  . T           . T                     T1       21.2





  double-blind pilot evaluation of intravenous glutathione treatment in PD was conducted      2.


              2.       .2. T       .    


THE ORIGINAL INTERNIST  21


                . T                            .             1           .    21    11     1  .                  .             .                    2.


   T   T        


      .. T                                 2.


                      . T                     . T                                  21.


       . on mitochondria- targeted antioxidants for treatment of PD both in clinical and clinical phases  21.


T  


                              . T                              . 21.


     . T            . T            . T                                              . 21.


      . established that N-Acetyl cysteine boosts the brain and blood levels of glutathione in Gaucher disease (GD) and PD 21.


T        


T  


        


       Muhlack to investigate the effect of Levodopa intake in patients suffering from PD 212.1


           .                    . T                 . 2       1  . T


                  . T                 212.2


   T    


    2


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52